Sponsor and exhibitor packages for the AMR Conference 2026
If you are interested in becoming a sponsor or exhibitor of the 10th AMR Conference, please choose a basic package (platinum, gold, silver or bronze) first. You can then customize your package with several add-ons. Prices for the add-ons vary depending on the chosen basic package. Please do not hesitate to contact us to receive a quote for your individual package or if you have any questions. All prices are net of 8.1% Swiss VAT.
Platinum
Includes 10 full conference tickets
12'000 CHF
Add-ons:
- Exhibition booth: + 500 CHF
- Speaker slot: + 500 CHF
- Branding of badges/lanyards: + 1’500 CHF
- Branding of conference session: + 2’000 CHF
- Branding of lunch or Apéro: + 2’000 CHF
- Private meeting room: + 2’500 CHF
- Pre-conference workshop: + 3’000 CHF
Silver
Includes 4 full conference tickets
5'000 CHF
Add-ons:
- Exhibition booth: + 1'000 CHF
- Speaker slot: + 1'700 CHF
- Branding of badges/lanyards: + 2’500 CHF
- Branding of conference session: + 3’200 CHF
- Branding of lunch or Apéro: + 5’000 CHF
- Private meeting room: + 4’500 CHF
- Pre-conference workshop: + 5’300 CHF
Gold
Includes 7 full conference tickets
8'500 CHF
Add-ons:
- Exhibition booth: + 700 CHF
- Speaker slot: + 1'000 CHF
- Branding of badges/lanyards: + 2'000 CHF
- Branding of conference session: + 2’500 CHF
- Branding of lunch or Apéro: + 3’200 CHF
- Private meeting room: + 3’500 CHF
- Pre-conference workshop: + 4’100 CHF
Bronze
Includes 2 full conference tickets
2'500 CHF
Add-ons:
- Exhibition booth: + 1'300 CHF
- Speaker slot: + 2'500 CHF
- Branding of badges/lanyards: + 3'000 CHF
- Branding of conference session: + 4’000 CHF
- Branding of lunch or Apéro: not available
- Private meeting room: not available
- Pre-conference workshop: not available
-
Basic sponsor packages
The packages include:
- Company profile on the website
- Sponsor logo on all conference promotional materials, the website, conference guide and signage
- Opportunity to display your marketing materials on the dedicated media table (max. 100 sets)
- Number of complimentary tickets depending on the choice of the basic package as shown above
- Additional tickets are available at 60% of the applicable rate
-
Add-on: exhibition booth
This add-on includes:
- All benefits of the chosen basic package, plus:
- 3 x 2 meters space in the exhibition area
- Larger booth spaces can be provided upon request
- All booths are equipped with back and side walls and a 230 V power socket
- Additional equipment can be ordered by the exhibitor at the Congress Center.
-
Add-on: speaker slot
This add-on includes:
- All benefits of the chosen basic package, plus:
- Inclusion with a speaker slot in one of the offered tracks
- To ensure the quality of the conference program, speaker slots will only be granted upon approval by the program committee.
-
Add-on: branding of badges and/or lanyards
This add-on includes:
- All benefits of the chosen basic package, plus:
- Conference name badges with the sponsor’s logo and/or branded lanyards
- Exclusivity
-
Add-on: branding of conference session
This add-on includes:
- All benefits of the chosen basic package, plus:
- Additional signage with sponsor's name and logo in the room during the session
- Presentation slot (10–15 min) at the beginning of the track (co-moderation optional)
-
Add-on: branding of lunch or Apéro
This add-on includes:
- All benefits of the chosen basic package, plus:
- Additional signage with sponsor's name and logo throughout the catering area during the lunch or Apéro
- Exclusivity
-
Add-on: private meeting room
This add-on includes:
- All benefits of the chosen basic package, plus:
- Option for one-to-one meetings in your own corporate partnering room at the event
- Separate room for approx. 15 people for the entire day, including coffee and soft drinks in the room
- Limited availability. Rooms will be provided on a first come, first
served basis. - Technical equipment for the room can be ordered by the sponsor at the Congress Center.
-
Add-on: pre-conference workshop
This add-on includes:
- All benefits of the chosen basic package, plus:
- Use of one of the conference rooms in the venue to hold your own pre-conference workshop
- Workshop can be held between 9:00 and 11:00 a.m. on 6 March.
- Room is provided with full conference equipment.
- Recording of your workshop can be provided on request at extra cost.
- Limited availability. Rooms will be provided on a first come, first
served basis.
Confirmed sponsors and exhibitors of the 10th AMR Conference 2026
Local Host
-
Basel
Basel is the most dynamic economic region in Switzerland and one of the most productive and innovative locations worldwide. Global leaders in the life sciences industry – Novartis, Roche, Syngenta, Lonza and others – have their headquarters in the Basel region. Basel is considered one of Europe’s top locations for life sciences and healthcare. This stimulating environment has given rise to a plethora of innovative research firms, including in the medical and biotechnology fields.
Gold
-
BioVersys
BioVersys AG focuses on life threatening infectious diseases. As a privately owned clinical stage Swiss biopharmaceutical company working on research & development of small molecules acting on novel bacterial targets, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2a) in collaboration with GSK and a consortium of the University of Lille.
-
INCATE
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, diagnostics and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
-
NCCR AntiResist
The National Center of Competence in Research AntiResist aims to bring about a paradigm shift in antibiotic research with an interdisciplinary approach that assembles a Swiss-wide network of research groups from the fields of clinical research, biology, chemistry, computation, engineering and pharmacology.
The research program is structured into three four-year phases covering strategically and dynamically evolving milestones. Research activities center around a better understanding of pathogen physiology in patients; developing axenic and tissue-based model systems mimicking patient environments; and engineering of novel screening platforms for the next generation of antibiotics.
NCCR AntiResist is funded by the Swiss National Science Foundation, and is based in the Biozentrum at its home institution of the University of Basel.
Silver
-
Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. The company has successfully developed and launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, Basilea has preclinical anti-infective assets in its portfolio and is listed on the SIX Swiss Exchange (SIX: BSLN). More on basilea.com.
-
DZIF
At the German Center for Infection Research (DZIF), more than 700 researchers from 35 institutions across Germany are working together to develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim is so-called translation: the rapid, effective implementation of research findings in clinical practice. The DZIF is thus paving the way for the development of new vaccines, diagnostics and drugs against infections. The DZIF is one of eight centers in the network of the German Centers for Health Research (DZG). Further information on the DZIF: www.dzif.de and on the DZG: deutschezentren.de.
-
Global AMR R&D Hub
The Global AMR R&D Hub is an international partnership that supports enhanced co-operation and collaboration in research and development efforts to address antimicrobial resistance (AMR) on a global scale. Established in response to a G20 call to action, the Hub brings together governments, international organizations, and other stakeholders to tackle AMR through collaboration and shared resources. By tracking and analyzing global funding data, identifying gaps, and fostering cross-sector partnerships, the Hub aims to support the development of sustainable ecosystem for the research and development of the solutions, tools, products and strategies we need to mitigate the ongoing impacts of AMR. The Hub's work supports a One Health approach, addressing AMR across human, animal, environmental and plant health sectors.
-
GARDP
We are a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. We receive vital support from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Bill & Melinda Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. We are GARDP, the Global Antibiotic Research & Development Partnership.
-
WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,850 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
Bronze
-
AUROBAC THERAPEUTICS
As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC THERAPEUTICS ambitions to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.
AUROBAC’s R&D strategy addresses this urgent need with patient- and pathogen-targeted programs. They are designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis.
We are currently seeking to strengthen our product portfolio, and we are particularly interested in co-developing or in-licensing products targeting Gram-Negative ESKAPE pathogens for the treatment of Acute Respiratory Infections (HAP, VAP), Sepsis and/or Septic Shock.
-
bioMérieux
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of international sales (outside of France).
bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
-
Debiopharm
-
Eltek Group
-
InfectoGnostics
Innovating Infection Diagnostics
InfectoGnostics is a public-private partnership that is breaking new grounds in infection diagnostics with over 30 collaborative partners. Partners at the research campus pioneer diagnostic methods to detect infectious agents and antibiotic resistance and aim for fast translation into of diagnostic products.
Visit our AMR 2025 booth with our partners Applyo, AID, Dynamic42, Leibniz Institute of Photonic Technology, LEG Thuringia, and Leibniz Health Technologies. Together, we offer market-ready laboratory tools and point-of-care tests for human, veterinary, and environmental diagnostics. Committed to addressing the global threat of multi-resistant infectious agents, the goal of InfectoGnostics is to provide accurate diagnoses before therapies. Join us in advancing diagnostic innovation into effective solutions.
-
Infex Therapeutics
Infex is a clinical-stage R&D infectious disease specialist, that acquires, develops, and licenses innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
-
Leibniz Health Technologies
LEIBNIZ HEALTH TECHNOLOGIES: A Research Alliance of the Leibniz Association
Providing technological solutions for unmet medical needs − this is the main focus of the 21 members of the interdisciplinary research alliance Leibniz Health Technologies (LHT).
To battle antimicrobial resistances, 18 Leibniz institutes and 3 spin-off companies are cooperating in interdisciplinary competence areas like Plasma Medicine, Point-of-Care Technologies or Bioactive Materials.
LHT's impactful technologies in the AMR domain include rapid point-of-care testing devices that utilize biophotonics and molecular assays. The Leibniz partners of the alliance also develop new antimicrobial biomaterials and coatings and create innovative spore-killing disinfectants. Furthermore, LHT partners are actively developing therapeutic systems for cold atmospheric plasma treatments to enhance wound healing and combat pathogens.
-
Novo REPAIR Impact Fund
Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.
The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects, which is anticipated to yield at least one new therapy reaching the market.
The REPAIR Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities.
REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.
-
Rime Bioinformatics
Rime Bioinformatics is a research and development biotechnology company with a focus on phage bioinformatics.
We develop services to speed up medical, agronomic and veterinary research.
Our technologies grant in-depth view of bacterial and bacteriophage genomes, which is an essential prerequisite in the R&D process that leads a phage to market. We work hard to make high-performance bioinformatics accessible and promote a safe use of phage therapy for the patients and the environment!
-
Selvita
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.
Selvita was established in 2007 and currently employs over 1000 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia.
Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. If you want to learn more about our services, visit our website.
-
tranScrip
tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle.
We build product strategies as well as design and execute development programmes and commercialisation activities.
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts, offer truly flexible bespoke solutions and support to maximise the value of products.
We help to expedite the development and commercialisation of products for the benefit of patients worldwide.
-
Vibiosphen